早期终止不影响黑色素瘤辅助免疫治疗结局
基于ADOREG真实世界注册数据,分析620例已切除III/IV期黑色素瘤患者接受辅助抗PD1治疗的生存结局。与常规52周治疗且治疗期间无复发者相比,提前终止治疗(<48周)者的2年无复发生存率更高(72.4% vs 51.5%),提示缩短治疗时长未导致更差结局。
要点
- 提前终止辅助抗PD1治疗未与更差的无复发生存或总生存相关。
- 提前终止原因中治疗相关副作用占45.3%,非毒性原因占54.7%。
- 未在治疗期间复发者中,常规疗程组2年RFS达84.1%。
核心结论
- 在已切除转移性黑色素瘤患者中,缩短抗PD1抗体治疗时长与更差结局无关。
研究设计与样本
- 基于前瞻性多中心真实世界皮肤癌注册登记ADOREG数据的分析,纳入620例完成辅助纳武利尤单抗或帕博利珠单抗治疗的AJCCv8 III/IV期已切除黑色素瘤患者。
主要发现
- 常规治疗时长组(52±4周且治疗期间无复发,n=229)与提前终止组(<48周,n=214)比较,提前终止组2年RFS为72.4%(95%CI 68.5-76.3),常规治疗时长且无复发组为84.1%(95%CI 81.5-86.7)。
- 常规治疗时长组加治疗期间复发组(A1+A2)的2年RFS为51.5%(95%CI 48.8-54.2)。
- 提前终止原因中治疗相关副作用占45.3%(n=97),非毒性原因占54.7%(n=117)。
- 仅在开始治疗后超过12个月复发的患者中,常规治疗时长组RFS有更好趋势。
临床怎么用
- 对于已切除III/IV期黑色素瘤接受辅助抗PD1治疗的患者,因毒性或其他原因提前终止治疗未显示不利影响,支持个体化评估治疗时长。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy. METHODS: From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A1) and patients with a premature end of treatment (<48 weeks; n = 214, B). Patients with disease recurrence during adjuvant treatment were included in cohort A2. RESULTS: The median duration of follow-up was 26.0 months [interquartile range (IQR) 18.0-34.0] in group A1 [median treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0 months (IQR 13.0-29.0)] in group B [median treatment duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early discontinuation were treatment-related side effects in 45.3% (n = 97) and other reasons than toxicity in 54.7% (n = 117). The 2-year rate of RFS was 72.4% (95% CI, 68.5-76.3) for patients in group B and 51.5% (95% CI, 48.8-54.2) in patients with regular and intended regular treatment duration (A1 plus A2). When analysing the patients who did not relapse during adjuvant treatment (A1), there was a significantly higher RFS rate of 84.1% (95% CI, 81.5-86.7). When only assessing patients with a recurrence after more than 12 months after initiation of therapy, there was a trend towards better RFS in patients with regular treatment duration. CONCLUSIONS: In patients with resected metastatic melanoma, shorter treatment duration with anti-PD1 antibodies is not associated with a worse outcome.
引用
- Tomsitz D, Livingstone E, Loquai C, et al. Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma. J Eur Acad Dermatol Venereol. 2025. PMID: 40119686. doi:10.1111/jdv.20650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。